Freeman, Léorah http://orcid.org/0000-0002-5696-1797
Longbrake, Erin E.
Coyle, Patricia K.
Hendin, Barry
Vollmer, Timothy
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Accepted: 5 October 2022
First Online: 9 November 2022
Declarations
:
: Medical writing support and open access publication was funded by Novartis Pharmaceuticals Corporation.
: Léorah Freeman has received consultancy fees from Celgene/Bristol Myers Squibb, EMD Serono, Genentech, Novartis, and TG Therapeutics; and has received program sponsorship from EMD Serono. She has grant support from EMD Serono, Genentech, NIH/NINDS, and PCORI. Erin E. Longbrake has received honoraria from Bristol Myers Squibb, Genentech, Janssen, NGM Bio, and TG Therapeutics. She has research support from Genentech, NIH K23NS107624, Race to Erase MS, andUL1 TR001863. Patricia K. Coyle received consultancy fees from Accordant, Alexion, Bayer, Biogen, Bristol Myers Squibb, Celgene, EMD Serono, Genentech/Roche, GlaxoSmithKline, Horizon Therapeutics, Janssen, Mylan, Novartis, Sanofi Genzyme, TG Therapeutics, and Viela Bio; and has received research grants from Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, and Novartis. Barry Hendin has received research support and advisory and speaking honoraria from Alexion, Biogen, EMD Serono, Genentech, Genzyme, and Novartis. Timothy Vollmer has received compensation for lectures and consultancy from Biogen, Celgene, EMD Serono, Genentech/Roche, Novartis, and Siranax; and has received research support from Anokion, Biogen, Celgene, F. Hoffmann-La Roche Ltd., Genentech, GW Pharma, Rocky Mountain Multiple Sclerosis Center, and TG Therapeutics.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors discussed and agreed on the concept for this article. Grace Jeong performed the literature search; Léorah Freeman, Erin E. Longbrake, Patricia K. Coyle, Barry Hendin, and Timothy Vollmer drafted and/or critically reviewed the work. All authors have read and approved the final submitted manuscript, and agree to be accountable for the work. This manuscript was developed in accordance with Good Publication Practice (GPP3) guidelines. Authors had full control of the content and made the final decision on all aspects of this publication.